{
  "docId": "019dd923-5fec-763b-95cd-961b6879cda6",
  "docSlug": "njj0K6xhOdjDOAwq28MP",
  "documentTitle": "See the 39-slide presentation that Moderna used to win over investors on its way to becoming the hottest company in biotech",
  "authorId": "Pitchdecks",
  "authorName": "Moderna",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.29,
  "pageNumber": 31,
  "pageCount": 39,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide is a partial view of a larger pipeline table, focusing on mRNA-2905.",
  "elementsJson": [
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95cd-961b6879cda6/31",
  "deckHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.06,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Abbreviations: GLP = good laboratory practice, IND = investigational new drug, CTA = clinical trial authorization; CMV = cytomegalovirus, CV = cardiovascular, HMPV = human metapneumovirus; PIV3 = parainfluenza virus 3, IL-12 = interleukin-12; VEGF-A = vascular endothelial growth factor A.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b04cf89-918b-41a8-9504-828956160cdf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.88,
        "x": 0.06,
        "y": 0.218
      },
      "kind": "table",
      "text": "Pipeline table with columns: Development Candidate, Lead, Indication/Target, Formulation, GLP Toxicology, IND/CTA Filed, Ph I, Ph II, Funding",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e346696f-eaa4-449d-a76b-3a02fcbb64aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.08
      },
      "kind": "title",
      "text": "Our Pipeline - Intratumoral Immuno-Oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84a458e9-4eb1-490d-a0c6-30eb073501ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}